[HTML][HTML] Targeted therapies for advanced non-small cell lung cancer
Lung cancer is a serious health problem and the leading cause of cancer death worldwide,
due to its high incidence and mortality. 85% of lung cancers are represented by the non …
due to its high incidence and mortality. 85% of lung cancers are represented by the non …
Targeted therapies for non-small cell lung cancer
WCM Dempke, T Suto, M Reck - Lung cancer, 2010 - Elsevier
Non-small cell lung cancer (NSCLC) accounts for approximately 80–85% of all cases of lung
cancer, and it is the most common cause of death in men and second only to breast cancer …
cancer, and it is the most common cause of death in men and second only to breast cancer …
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer
Z Wang, Y Xing, B Li, X Li, B Liu, Y Wang - Molecular biomedicine, 2022 - Springer
Lung cancer is the leading cause of cancer-related mortality worldwide. The discovery of
tyrosine kinase inhibitors effectively targeting EGFR mutations in lung cancer patients in …
tyrosine kinase inhibitors effectively targeting EGFR mutations in lung cancer patients in …
Targeted therapy in non-small-cell lung cancer—is it becoming a reality?
F Janku, DJ Stewart, R Kurzrock - Nature reviews Clinical oncology, 2010 - nature.com
Abstract Treatment outcomes in advanced or metastatic non-small-cell lung cancer (NSCLC)
remain unsatisfactory, with low long-term survival rates. Palliative chemotherapy offers a …
remain unsatisfactory, with low long-term survival rates. Palliative chemotherapy offers a …
NSCLC as the paradigm of precision medicine at its finest: the rise of new druggable molecular targets for advanced disease
A Michelotti, M de Scordilli, E Bertoli… - International Journal of …, 2022 - mdpi.com
Standard treatment for advanced non-small cell lung cancer (NSCLC) historically consisted
of systemic cytotoxic chemotherapy until the early 2000s, when precision medicine led to a …
of systemic cytotoxic chemotherapy until the early 2000s, when precision medicine led to a …
[PDF][PDF] NSCLC: an update of driver mutations, their role in pathogenesis and clinical significance
RC Black, H Khurshid - Rhode Island medical journal, 2015 - rimed.org
Lung cancer is the most common malignancy in the US and causes the most cancer-related
deaths. Non-smallcell lung carcinoma (NSCLC) accounts for the majority of cases. NSCLC …
deaths. Non-smallcell lung carcinoma (NSCLC) accounts for the majority of cases. NSCLC …
Recent progress in targeted therapy for non-small cell lung cancer
Y Xiao, P Liu, J Wei, X Zhang, J Guo… - Frontiers in Pharmacology, 2023 - frontiersin.org
The high morbidity and mortality of non-small cell lung cancer (NSCLC) have always been
major threats to people's health. With the identification of carcinogenic drivers in non-small …
major threats to people's health. With the identification of carcinogenic drivers in non-small …
Successes and limitations of targeted cancer therapy in lung cancer
K Suda, T Mitsudomi - Successes and Limitations of Targeted Cancer …, 2014 - karger.com
Human cancers usually evolve through multistep processes. These processes are driven by
the accumulation of abundant genetic and epigenetic abnormalities. However, some lung …
the accumulation of abundant genetic and epigenetic abnormalities. However, some lung …
Advances in the development of molecularly targeted agents in non-small-cell lung cancer
Non-small-cell lung cancer (NSCLC) remains a significant global health challenge and the
leading cause of cancer-related mortality. The traditional 'one-size-fits-all'treatment …
leading cause of cancer-related mortality. The traditional 'one-size-fits-all'treatment …
Targeted therapy for lung cancer
F Petrosyan, H Daw, A Haddad, T Spiro - Anti-cancer drugs, 2012 - journals.lww.com
Lung cancer is considered the number one killer among all cancers. Recent observations
have altered the treatment paradigm for non-small-cell lung cancer (NSCLC). The discovery …
have altered the treatment paradigm for non-small-cell lung cancer (NSCLC). The discovery …